TISIDB

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF07524 Bromodomain associated PF00628 PHD-finger
Function	Transcription factor TFIID is one of the general factors required for accurate and regulated initiation by RNA polymerase II. TFIID is a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. Required in complex with TBPL2 for the differentiation of myoblasts into myocytes. The complex replaces TFIID at specific promoters at an early stage in the differentiation process.

> Gene Ontology [ TOP ]
Biological Process	GO:0006352 DNA-templated transcription, initiation GO:0006354 DNA-templated transcription, elongation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0006368 transcription elongation from RNA polymerase II promoter GO:0032507 maintenance of protein location in cell GO:0034504 protein localization to nucleus GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0045185 maintenance of protein location GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051235 maintenance of location GO:0051457 maintenance of protein location in nucleus GO:0051651 maintenance of location in cell GO:0072331 signal transduction by p53 class mediator GO:0072595 maintenance of protein localization in organelle GO:1901796 regulation of signal transduction by p53 class mediator
Molecular Function	GO:0002039 p53 binding
Cellular Component	GO:0000428 DNA-directed RNA polymerase complex GO:0005667 transcription factor complex GO:0005669 transcription factor TFIID complex GO:0016591 DNA-directed RNA polymerase II, holoenzyme GO:0030880 RNA polymerase complex GO:0044798 nuclear transcription factor complex GO:0055029 nuclear DNA-directed RNA polymerase complex GO:0061695 transferase complex, transferring phosphorus-containing groups GO:0090575 RNA polymerase II transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03022 Basal transcription factors
Reactome	R-HSA-1643685: Disease R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-167161: HIV Transcription Initiation R-HSA-5663205: Infectious disease R-HSA-162599: Late Phase of HIV Life Cycle R-HSA-167162: RNA Polymerase II HIV Promoter Escape R-HSA-674695: RNA Polymerase II Pre-transcription Events R-HSA-73776: RNA Polymerase II Promoter Escape R-HSA-73857: RNA Polymerase II Transcription R-HSA-75953: RNA Polymerase II Transcription Initiation R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation R-HSA-167172: Transcription of the HIV genome R-HSA-3700989: Transcriptional Regulation by TP53

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03022 Basal transcription factors

Reactome

R-HSA-1643685: Disease
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167161: HIV Transcription Initiation
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TAF3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TAF3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 1.22	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TAF3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.136	0.648
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.603	0.568
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.21	0.811
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.029	0.9
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.085	0.968
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.039	0.989
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.303	0.215
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.386	0.694
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.209	0.849
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.427	0.601
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.959	0.379
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.059	0.411

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TAF3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	5.9	8.4	0.613
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAF3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAF3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAF3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAF3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TAF3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TAF3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TAF3
Name	TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDa
Aliases	TAF140; TAFII140; TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kD; TAFII-14 ......
Chromosomal Location	10p15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TAF3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TAF3